Roth Capital Partners raised its price target for GlycoMimetics (NASDAQ:GLYC) to $35 from $25 after the company agreed with the Dutch hematological oncology foundation, HOVON, to move towards a 140-patient study of GMI-1271 in combination with decitabine in newly-diagnosed patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) unfit for chemotherapy induction.Read More
Roth Capital Partners initiated coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $8 price target. The stock closed at $1.69 on Dec. 20.Read More
Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).Read More
Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital.
Proceeds will be used for a multi-center, Phase 2b clinical trial with the company’s lead product, Astarabine, for the treatment of acute myeloid leukemia (AML).Read More
Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday.
Analyst Stephen Willey writes that recently-announced Phase 3 data, demonstrating Vyxeos confers a statistically-significant improvement in overall survival versus traditional cytarabine/daunorubicin chemotherapy (“7+3”) in patients aged 60-to-75 with high-risk/secondary acute myeloid leukemia (AML), represents the first meaningful therapeutic advancement in AML since conventional “7+3” chemotherapy became the backbone of intensive induction therapy more than 40 years ago.Read More
Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months.
The Phase 1/2a trial is an open-label study to evaluate the safety and efficacy of Astarabine as single agent in adults with acute myeloid leukemia (AML) and relapsed/refractory acute lymphoblastic leukemia (ALL).Read More
Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday.
“In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid leukemia (AML),” writes analyst Raghuram Selvaraju.Read More